Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809705 | 0.84 | KDM4E (0.63) | KDM4EL3MBTL1ALDH1A1POLBNOTUM | |
| SCHEMBL4806681 | 0.83 | KDM4E (0.68) | KDM4EL3MBTL1ALDH1A1POLBNOTUM | |
| SCHEMBL31182095 | 0.78 | KDM4E (0.67) | KDM4EL3MBTL1ALDH1A1POLBNOTUM | |
| SCHEMBL11548268 | 0.78 | KDM4E (0.67) | KDM4EL3MBTL1ALDH1A1POLBNOTUM | |
| SCHEMBL3149021 | 0.77 | KDM4E (0.52) | KDM4EL3MBTL1ALDH1A1POLBNOTUM | |
| SCHEMBL25784150 | 0.76 | KDM4E (0.66) | KDM4EL3MBTL1ALDH1A1POLBNOTUM | |
| SCHEMBL23875654 | 0.74 | HSD17B3 (0.68) | KDM4EL3MBTL1ALDH1A1POLBNOTUM | |
| SCHEMBL11108730 | 0.74 | HSD17B3 (0.66) | KDM4EL3MBTL1ALDH1A1POLBNOTUM | |
| SCHEMBL19224983 | 0.74 | HSD17B3 (0.66) | KDM4EL3MBTL1ALDH1A1POLBNOTUM | |
| SCHEMBL30982111 | 0.74 | HSD17B3 (0.68) | KDM4EL3MBTL1ALDH1A1POLBNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288258-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | DIANA GUY D | 2005-12-29 | — | — | US | disclosed |
| US-20050113366-A1 | Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses | UNIVERSITE LOUIS PASTEUR (ETABLISSEMENT PUBLIC A CARACTERE SCIENTIFIQUE, CULTUREL ET PROFESSIONNEL) (FR) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113366-A1 | Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses | GABRB1, GABRA1, GABRA5 | KDM4E 1917/4885L3MBTL1 2407/4885ALDH1A1 590/4885 |
| US-20050288258-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | MAVS, HAVCR2, ZC3HAV1 | KDM4E 3307/4885L3MBTL1 1184/4885ALDH1A1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.